Analytical Technology Introductions Planned for Pittcon 2013 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Analytical Technology Introductions Planned for Pittcon 2013


The Pittcon 2013 Exposition, which takes place March 17-21 at the Pennsylvania Convention Center in Philadelphia, features emerging analytical technologies for analytical chemistry, drug discovery and development, nanotechnology, life sciences, and other disciplines. Instrument manufacturers frequently introduce new products or announce updates to current technologies at the event.

The exposition floor includes 1,926 booths and 18 seminar rooms, hosting 1,011 exhibitors (as of March 1, 2013) displaying products and services used by the scientific community in industrial, academic, and government labs. A mini-museum display of instrumentation, presented by the Chemical Heritage Foundation, celebrates the 100th anniversary of mass spectrometry.

The conference program features workshops, symposia, and short courses on chromatography, molecular and atomic spectroscopy, electrochemistry, mass spectrometry, and lab-on-chip technology.

Waters Corp. Updates Instruments and Software

Shimadzu Scientific Instruments Adds Chromatography Instruments and Software

Thermo Fisher Scientific Introduces Software, Instruments, and Consumables

Mettler Toledo Introduces Mechanical Analyzer

Rigaku Raman Upgrades Handheld Analyzer

Bruker Introduces Mass Spectrometers, NMR Modules

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here